Objective Capital Partners Strengthens Its Healthcare & Life Sciences Investment Banking Practice with the Addition of Jack J. Florio

Objective Capital Partners Strengthens Its Healthcare & Life Sciences Investment Banking Practice with the Addition of Jack J. Florio

San Diego, CA- January 18, 2017 – Objective Capital Partners, a leading M&A investment banking firm focused on transactions for companies with enterprise values up to $500 million, is pleased to welcome the addition of Jack J. Florio fueling its ability to secure and execute high quality deals in the healthcare & life sciences space.  Mr. Florio brings more 40 years’ of global life sciences experience in major pharmaceutical, biotechnology, medical devices and digital health companies.  He has held senior management roles in both small and large companies including CEO, Corporate Development and Business Development.  He will serve as Managing Director and help with execution of the firm’s investment banking activities in the healthcare & life science space alongside David H. Crean, Ph.D..

“The Objective Capital team is excited to have Jack onboard.  He is an experienced life science professional, investor and deal maker.  His presence and involvement will help the firm’s growing healthcare and life science practice in executing M&A, licensing and capital raising transactions for life science entrepreneurs and business owners”, stated Dr. Crean, Managing Director. “I am excited to work alongside Jack and have him join our talented team of professionals at Objective Capital as we endeavor to become the premier M&A investment banking firm serving business owners in Southern California within numerous industries including healthcare & life sciences.”

About Jack J. Florio

Jack J. Florio began his life sciences career at Eli Lilly and Company where he spent almost 30 years in positions of increasing responsibility supporting both domestic and foreign markets in sales, marketing and market research, product and therapeutic area leadership and global pricing. In his last role at Lilly, he successfully created the Late Life Cycle Products Team, a group responsible for the planning and divestiture of products as they moved into the latter part of their life cycle. Over the course of his career, he covered multiple therapeutic areas including neuroscience, anti-infectives, liver disease, pain and inflammation, gastrointestinal disorders, metabolic diseases and oncology.

In the past 14 years, in addition to opening the West Coast office for Brinson Patrick Securities as an investment banker, Mr. Florio held executive roles in different companies in areas of corporate development, business development and as Chief Executive Officer. He currently serves in formal advisory roles on several companies in the pharmaceutical, medical device and digital health spaces.

Concurrent with his role at Objective Capital, Mr. Florio is a Partner at Deallus Consulting, a UK based Global life sciences consultancy.  He is also on the BIOCOM Board of Directors and serves a role on BIOCOM’s Capital Development Committee.  He is an active investor in life science companies with Tech Coast Angels since 2001 where he served on the Board of Directors for 8 years. He is currently on the BIO 2017 International Planning Committee and the InvestSW Venture Madness Review Committee.

Mr. Florio holds both a Masters of Business Administration Degree with a marketing concentration as well as an APC in Management from New York University. Additionally, he holds a Bachelor of Science Degree in Pharmacy from Columbia University, College of Pharmaceutical Sciences. Mr. Florio holds FINRA Series 7 and 63 licenses.

About Objective Capital Partners

Objective Capital Partners is a leading M&A investment banking firm whose Principals have collectively engaged in more than 500 successful transactions serving the transaction needs of growth stage and mid-size companies. The executive team has a unique combination of investment banking, private equity, and business ownership experience that enables Objective Capital Partners to provide large enterprise caliber investment banking services to companies with annual revenues up to $500 million. Services include sale transactions, equity and debt capital raises and comprehensive advisory services. The firm uses a proprietary process to work to achieve premium company valuation, strong pricing, and high client satisfaction rates post-sale. The firm’s industry expertise includes: software and hardware technology, life sciences, business services, IT services, healthcare services, biotech, consumer products and specialized manufacturing. Securities and investment banking services are offered through BA Securities, LLC Member FINRA, SIPC. The Principals of Objective Capital are Registered Representatives of BA Securities. Objective Capital Partners and BA Securities are separate and unaffiliated entities. Additional information on Objective Capital Partners is available at www.objectivecp.com.

# # #

Objective Capital Partners Contact:

David H. Crean, Ph.D.

Managing Director, Healthcare & Life Sciences

3636 Nobel Drive, Suite 160

San Diego, CA 92122

(858) 461-9490



San Diego Venture Group (SDVG) Adds Trever Acers to Its Board of Directors


I would like more information about...

Connect With Us